DexCom, Inc. announced a new continuous glucose monitoring system. This system is called Dexcom Flex. It helps adults with Type 2 diabetes. It is for people not using intensive insulin therapy.
The new system will be available in Germany soon. It tracks glucose levels 24/7. Users see data on a smartphone, smartwatch, or receiver. It removes the need for routine fingerpricks.
The device expands access to CGM technology. It helps a broader Type 2 diabetes population. Hundreds of millions of people live with this disease globally. Many historically had limited access to these tools.
Germany is expanding its digital health tools. The new system supports healthcare providers. It broadens access across diverse patient groups.
The system provides real-time glucose data. It offers personalised behavioural insights and simplified tracking tools. Users can choose to log food and activity.
This helps users see how food and exercise impact glucose patterns. Daily activities and long-acting insulin impact patterns too. The system includes optional low glucose alerts. These customisable alerts help prevent hypoglycemic events.
Personalised Diabetes Care Benefits
Studies show CGM use may reduce diabetes-related hospitalisations. It is associated with reduced long-term cardiovascular risks. It is also associated with reduced mortality.
Users report improved confidence. They understand the impact of food on glucose levels better. The systems help users reduce HbA1c. They also increase time spent in target glucose ranges.
“The development of Dexcom Flex reflects a shift toward personalised diabetes guidance,” said Ian Hanson, senior vice president of engineering at Dexcom. “We strongly believe that personalised diabetes care is what helps people adopt the new habits and behavioural changes that lead to meaningful results. Dexcom Flex has been designed to support people earlier in their Type 2 diabetes journey, delivering a more tailored experience while maintaining the accuracy and reliability associated with Dexcom technology.”
The product design process places people at the centre. It creates a personalised diabetes guidance experience. It avoids a one-size-fits-all approach.
“Launching Dexcom Flex in Germany reflects our continued focus on expanding access to CGM,” said Alexander Fröhlich, vice president and general manager DACH at Dexcom. “As personalisation becomes increasingly important in Type 2 diabetes care, Flex enables a more tailored approach to glucose monitoring. By supporting people earlier in their Type 2 journey, before they require intensive insulin therapy, Flex may help improve long‑term health outcomes and contribute to meaningful reductions in diabetes-related complications.”
The device assists people earlier in their diabetes journey. It supports informed decision-making. It builds user confidence over time.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
